Adversarial validation as Big Pharma re-enters the CNS pipeline.
The CNS pipeline is in the fastest rewrite cycle since the category was abandoned a decade ago. Kisunla and Leqembi reached commercial deployment in 2023 and 2024 after three decades of anti-amyloid failures. AbbVie, BMS, and Biogen executed more than $30B in neuroscience acquisitions across a 24-month window. AimwellBio runs a dedicated neurology corpus of 654 source-cited signals, built from PubMed, ClinicalTrials.gov, SEC EDGAR, and FDA ingest, then post-process filtered to a 58.4% retention rate against CNS and neurodegenerative terminology. Source, date, confidence grade, and method on every entry. No generative summaries.
For two decades, the anti-amyloid hypothesis was a graveyard. Lilly's Kisunla (donanemab) received FDA approval in July 2024; Eisai-Biogen's Leqembi (lecanemab) reached full approval in July 2023 after the Aduhelm controversy. The class is now in commercial deployment with infusion-center bottlenecks, ARIA monitoring requirements, and ministry-tier reimbursement decisions. Every Alzheimer's competitor (Roche's gantenerumab failure, Biogen's next-gen tau and TREM2 programs) reads against this benchmark.
AbbVie acquired Cerevel for $8.7B in 2024 to add emraclidine and tavapadon. BMS acquired Karuna for $14B to add the muscarinic schizophrenia agent KarXT (now Cobenfy, FDA-approved September 2024). Biogen acquired Reata for $7.3B for SKYCLARYS in Friedreich ataxia. Specialty neuro biotechs (Acadia, Sage, Praxis, Axsome, Intra-Cellular, Neurocrine, Denali, Alector, Voyager, Prothena) sit in active M&A read-through territory.
The CGRP-migraine class (Nurtec, Qulipta, Ubrelvy, Aimovig, Emgality, Ajovy) is consolidating into reimbursement reality; the psychedelic-adjacent biotechs (Compass, atai, MindMed, GH Research) are forcing the FDA to draw speculative-evidence boundaries; the anti-CD20 MS class (Ocrevus, Kesimpta) and the SOD1-ALS programs (Qalsody) are rewriting rare-neuro economics. Provenance, source method, and confidence on every signal. No hallucination tolerance for ministry-scale procurement.
Built from a focused ingest of PubMed, ClinicalTrials.gov, SEC EDGAR, and FDA queries scoped to neurology, CNS, and neurodegenerative terminology, then post-process filtered against drug-name false positives where the trial was not a neurological indication. Most CNS intelligence products do not tell you what they filtered out or why. We publish the retention methodology. 1,119 raw signals, 654 high-confidence retained, 58.4% retention rate.
Peer-reviewed CNS literature: amyloid & tau biology, alpha-synuclein, CGRP mechanism, anti-CD20 MS outcomes, psychedelic-assisted therapy trials, neuroinflammation.
10-Q, 10-K, and 8-K filings from Big Pharma neuro and specialty neuro biotechs. Pipeline disclosure, M&A language, royalty terms, and indication-expansion intent.
Active and recently completed CNS interventional trials. Phase 2 / Phase 3 readouts, sponsor-flagged combination studies, sovereign-region site enrollment.
1,119 raw signals → 654 retained after drug-name false-positive filtering. The retention discipline is the cited methodology.
Every corpus has a shape. The Johari model maps what this corpus knows, what it doesn't yet track, and what's been deliberately obscured in corporate disclosure. Understanding the shape is part of the methodology.
Each entity is mapped into AIMN:ATLAS with scheduled-refresh SEC, ClinicalTrials.gov, and PubMed coverage. 5 sovereign-anchored institutions across KSA / GCC / MENA are flagged. Click any name to open its company dossier.
The GCC and MENA cluster represents a high-density sovereign-procurement opportunity for neurology. SFDA approvals, MOH formulary decisions on anti-amyloid agents and CGRP biologics, neurology-center capacity expansion, and cross-border clinical infrastructure across Riyadh, Abu Dhabi, Doha, Amman, and Beirut are trackable through the indication-aware pipeline. Vision 2030 procurement cycles for Alzheimer's, MS, ALS, and Parkinson's therapies close inside windows measured in months.
New PubMed, ClinicalTrials.gov, and SEC EDGAR entries ingested on each corpus refresh cycle. Source dates, confidence grades, and provenance metadata update with each ingest run.
654 signals and 42 entities reflect the May 2026 indexed corpus. These counts update at the next scheduled corpus rebuild, not in real time.
5-source adversarial PROCEED/DELAY/KILL verdict with HIGH/MED/LOW confidence score and citation-resolution gate. Member access. ~90s generation on demand.
42-entity interactive corporate and geographic map. Signal counts per entity, relationship graph, sovereign anchor flags. Invite-only during beta.
Analyst estimate from IQVIA 2024 Neuroscience Report. Not recalculated on corpus refresh. Manually updated on major market report releases.
Neurology is structurally a multi-vertical: Alzheimer's, Parkinson's, ALS, multiple sclerosis, epilepsy, CGRP-migraine, behavioral health, neuroinflammation, stroke, and rare neuro all sit inside the same upstream feed. AimwellBio resolves the overlap as a first-class corpus with disease-specific secondary tags applied at filter time, so investigators can drill from Neurology → Alzheimer's → anti-amyloid in one click.
Anti-amyloid, muscarinic schizophrenia, and ASO platform acquisitions set a $30B benchmark in 24 months. The next wave — CGRP consolidation, psychedelic-adjacent regulation, rare-neuro ASO licensing — requires source-cited, adversarially validated intelligence, not IR talking points. AIMN:VERDICT delivers PROCEED/DELAY/KILL with confidence score and citation chain before the committee meets.
CGRP class consolidation (7 agents), anti-CD20 MS (Ocrevus, Kesimpta), and the new muscarinic entrant (Cobenfy) require continuous competitive intelligence. The corpus tracks 104 active CNS trials, ARIA monitoring protocol disclosure, and label comparison across class members. No commercial product shows the evidence shape of each competitor's trial dataset the way AIMN:VERDICT does.
Kisunla and Leqembi require SFDA approval, formulary listing, infusion-center infrastructure, and ARIA monitoring protocols before Vision 2030 procurement cycles can close. The 5 sovereign CNS anchors (KFSH, Cleveland Clinic Abu Dhabi, HMC, KHCC, AUB) are tracked entities. Ministry-grade briefings delivered under NDA.
Biogen/Ionis/Wave ASO licensing structures, SKYCLARYS in Friedreich ataxia, tofersen in SOD1-ALS, and the rare-neuro cross-tag give specialty pharma the competitive map they cannot build from PubMed reads alone. Signal-tier access delivers the corpus as a structured intelligence feed into existing commercial workflows.
Big Pharma has deployed $30B in neuroscience acquisitions in 24 months. Anti-amyloid is in commercial deployment. The CGRP class is consolidating. The psychedelic-adjacent space is forcing FDA classification decisions. AimwellBio runs the adversarial validation layer that separates the defensible thesis from the IR talking point.
Ministry procurement or NDA briefing? Discuss sovereign deployment →